Active, not recruitingPhase 1NCT05716009
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
Studying Diphtheria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Alexander Ambinder, MDSKCCC Johns Hopkins Medical Institution
- Intervention
- Dose Escalation -tagraxofusp-erzs(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Collaborators
StemlineTherapeutics, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05716009 on ClinicalTrials.govOther trials for Diphtheria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07203755Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined VaccineCanSino Biologics Inc.
- RECRUITINGPHASE4NCT07097012Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in PregnancyCanadian Immunization Research Network
- RECRUITINGPHASE3NCT07112144Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical TrialChangchun BCHT Biotechnology Co.
- RECRUITINGPHASE1, PHASE2NCT06997627A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy AdultsGC Biopharma Corp
- RECRUITINGNANCT06815250Enhancing Maternal Vaccine Knowledge and Uptake: the InTroDuce-Programme TrialUniversiti Putra Malaysia
- RECRUITINGPHASE2, PHASE3NCT06947499A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesLG Chem
- ENROLLING BY INVITATIONPHASE4NCT07005726BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in AfricaBandim Health Project
- ACTIVE NOT RECRUITINGPHASE3NCT06857370Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined VaccineCanSino Biologics Inc.